Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12 2023 - 4:05PM
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology
company developing medicines for broad populations of cancer
patients with an initial aim to develop a universal-RAS therapy,
today announced that management will present at the 22nd Annual
Needham Virtual Healthcare Conference to discuss the company’s
pipeline, platform, and business strategy. Participating will be
Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott
Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief
Scientific Officer, and Mallory Morales, CPA, Vice President of
Finance, Treasurer.
Format: Virtual Presentation and 1x1 Investor MeetingsVirtual
Presentation: April 19 from 12:45 - 1:25 pm ET in Track 1
The presentations will be webcast live and archived for 30 days
in the Investor Relations section of Immuneering’s website
at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation Immuneering
is a clinical-stage oncology company developing medicines for broad
populations of cancer patients with an initial aim to develop a
universal-RAS therapy. The company aims to achieve universal
activity through deep cyclic inhibition of the MAPK pathway,
impacting cancer cells while sparing healthy cells. Immuneering’s
lead product candidate, IMM-1-104, is in a Phase 1/2a study in
patients with advanced solid tumors harboring RAS mutations. The
company’s development pipeline also includes IMM-6-415, a
universal-MAPK program, as well as several early-stage programs.
For more information, please visit www.immuneering.com.
Media Contact:Gina Nugent Nugent
Communications 617-460-3579 gina@nugentcommunications.com
Investor Contacts: Laurence
Watts Gilmartin
Group 619-916-7620 laurence@gilmartinir.com
or
Kiki Patel, PharmD Gilmartin
Group 332-895-3225kiki@gilmartinir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024